Results 231 to 240 of about 5,873,759 (302)
Interaction of class III cellobiose dehydrogenase with lytic polysaccharide monooxygenase
The activity of lytic polysaccharide monooxygenase (LPMO) is supported by its auxiliary enzyme cellobiose dehydrogenase (CDH). The catalytic activity of both enzymes is coupled by electron transfer and a cyclic cascade generating substrates for both enzymes – hydrogen peroxide for LPMO and oxidized and non‐oxidized cellobiose and cello‐oligosaccharide ...
Angela Giorgianni+4 more
wiley +1 more source
Conserved function of the HAUS6 calponin homology domain in anchoring augmin for microtubule branching. [PDF]
Würtz M+13 more
europepmc +1 more source
Fervidibacter sacchari is a member of the bacterial phylum Armatimonadota, only a few of which have been cultivated. It is a hyperthermophilic polysaccharide degradation specialist. We show that a secreted enzyme, Fsa02490Xyn, is an endoxylanase belonging to glycoside hydrolase family 10.
Nicole Torosian+10 more
wiley +1 more source
Introduction of new quinolone-2-thio-acetamide-propane hydrazide-benzimidazole derivatives as new α-glucosidase and α-amylase inhibitors. [PDF]
Nikfar P+9 more
europepmc +1 more source
ТермокаталитичеÑкий гидрогенолиз горючих Ñланцев
Zhaksyntay Kairbekov+3 more
openalex
Matrix: a complex amalgam of structures and functions in tumor microenvironment
The matrix is a dynamic, intricate three‐dimensional mesh of biomolecules with both structural and functional properties. This review deals with the complexity of this ‘molecular amalgam’ in the tumor microenvironment and highlights its importance in the maintenance and evolution of tumors by describing certain matrix biomolecules, such as ...
Spyros S. Skandalis+3 more
wiley +1 more source
Modelling US health equity impacts of emicizumab for severe haemophilia A: aggregate distributional cost-effectiveness analysis. [PDF]
Majda T, Lee JS, Curtis R, Kowal SL.
europepmc +1 more source
Phenotypic plasticity in a newly established set of EGFR inhibitor‐adapted NSCLC cell lines during adaptation and in established cell lines. Here, we introduce novel sublines of the EGFR‐mutant non‐small cell lung cancer (NSCLC) cell lines HCC827 and HCC4006 adapted to the EGFR kinase inhibitors gefitinib (HCC827rGEFI2μm, HCC4006rGEFI1μm), erlotinib ...
Tharsagini V. Nanthaprakash+6 more
wiley +1 more source